
GLP-1 Medications Show Small Increase in Bone-Health Risks, Study Finds
A five-year study of 73,483 people starting GLP-1 medications (e.g., semaglutide, liraglutide, dulaglutide, exenatide) and 73,483 matched controls found small but statistically significant increases in osteoporosis (0.9%), gout (0.8%), and osteomalacia (0.1%) among GLP-1 users. The study does not prove causation and factors like diet and exercise were not analyzed. The findings could inform bone-health surveillance and more personalized prescribing, though GLP-1 therapies also offer metabolic benefits and long-term effects require further study.













